Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.

Saved in:
Bibliographic Details
Title: Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.
Authors: Hong SD; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Wang YS; West China Hospital of Sichuan University, Chengdu, China., Zhao HY; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Zhao YY; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Wang QM; Henan Cancer Hospital, Zhengzhou, China., Ma YX; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Li YS; Chongqing Cancer Hospital, Chongqing, China., Huang Y; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Yang YP; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Fu ZM; Renmin Hospital of Wuhan University, Wuhan, China., Chen LK; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Zhou F; Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China., Yang J; The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Li XY; The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Hou X; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Zhou NN; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Sun LH; The First Affiliated Hospital of Nanchang University, Nanchang, China., Zhang GF; Xinxiang Central Hospital, Xinxiang, China., Cui JW; The First Hospital of Jilin University, Changchun, China., Wu L; Hunan Provincial Cancer Hospital, Changsha, China., Chen G; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Zhang YX; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Wang HY; Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, China., Lv DQ; Taizhou Hospital of Zhejiang Province, Taizhou, China., Shi JH; Linyi Cancer Hospital, Linyi, China., Jiang B; Yunnan Cancer Hospital, Kunming, China., Li C; Changzhou First People's Hospital, Changzhou, China., Li XL; Liaoning Cancer Hospital & Institute, Shenyang, China., Tang KJ; The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Yu Y; Harbin Medical University Cancer Hospital, Harbin, China., Ji YH; The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China., He ZY; Fujian Cancer Hospital, Fuzhou, China., Zhu Y; Sichuan Biokin Pharmaceutical Co. Ltd, Chengdu, China., Zhu H; Sichuan Biokin Pharmaceutical Co. Ltd, Chengdu, China., Xiao S; Baili-Bio (Chengdu) Pharmaceutical Co. Ltd, Chengdu, China., Zhou CC; Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China; Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address: caicunzhoudr@163.com., Zhang L; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China. Electronic address: zhangli@sysucc.org.cn., Fang WF; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China. Electronic address: fangwf@sysucc.org.cn.
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Jun; Vol. 37 (6), pp. 813-824. Date of Electronic Publication: 2026 Jan 27.
Publication Type: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1569-8041
DOI:10.1016/j.annonc.2026.01.009